Subscriber Authentication Point
lvrea
Home All issues Volume 26 / No 4 (Juillet 2017) Méd. Intensive Réa., 26 4 (2017) 285-295 References
Free Access
Issue
Méd. Intensive Réa.
Volume 26, Number 4, Juillet 2017
Médecine interne et transversalité
Page(s) 285 - 295
Section Mise au point / Update
DOI https://doi.org/10.1007/s13546-017-1284-x
Published online 03 June 2017
  • Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL, (1980) Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma. Am J Med 68: 486–491 [CrossRef] [PubMed] [Google Scholar]
  • Howard SC, Jones DP, Pui CH, (2011) The tumor lysis syndrome. N Engl J Med 364: 1844–1854 [CrossRef] [PubMed] [Google Scholar]
  • Aulagnon F, Lapidus N, Canet E, Galicier L, Boutboul D, Peraldi MN, Reuter D, Bernard R, Schlemmer B, Azoulay E, Zafrani L, (2015) Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis 65: 851–859 [CrossRef] [PubMed] [Google Scholar]
  • Razis E, Arlin ZA, Ahmed T, Feldman EJ, Puccio C, Cook P, Chun HG, Helson L, Mittelman A, (1994) Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol 91: 171–174 [CrossRef] [PubMed] [Google Scholar]
  • Kedar A, Grow W, Neiberger RE, (1995) Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hematol Oncol 12: 129–134 [CrossRef] [PubMed] [Google Scholar]
  • Hande KR, Garrow GC, (1993) Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med 94: 133–139 [CrossRef] [PubMed] [Google Scholar]
  • Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology, (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169: 661–671 [CrossRef] [PubMed] [Google Scholar]
  • Cairo MS, Bishop M, (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127: 3–11 [CrossRef] [PubMed] [Google Scholar]
  • Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D, Raffoux E, Lengline E, Chevret S, Darmon M, Azoulay E, (2013) Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PloS One 8: e55870 [CrossRef] [PubMed] [Google Scholar]
  • Kellum JA, Lameire N; KDIGO AKI Guideline Work Group, (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17: 204 [CrossRef] [PubMed] [Google Scholar]
  • Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C; FAB LMB96, International Study Committee, (2006) Results of a randomized international study of high risk central nervous system B-non-Hodgkin’s lymphoma and B-acute lymphoblastic leukemia in children and adolescents. Blood 109: 2736–2743 [Google Scholar]
  • Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH, (2005) Efficacy and safety of rasburicase, a recombinant urate oxidase (ElitekTM), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 19: 34–38 [PubMed] [Google Scholar]
  • Locatelli F, Rossi F, (2005) Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 147: 61–68 [PubMed] [Google Scholar]
  • Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A, (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95: 563–573 [CrossRef] [PubMed] [Google Scholar]
  • Bose P, Qubaiah O, (2011) A review of tumour lysis syndrome with targeted therapies and the role of rasburicase: TLS with targeted therapies and role of rasburicase. J Clin Pharm Ther 36: 299–326 [CrossRef] [PubMed] [Google Scholar]
  • Mirrakhimov AE, Ali AM, Khan M, Barbaryan A, (2014) Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors 6: 5389 [CrossRef] [PubMed] [Google Scholar]
  • Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S, Kamijo A, Komatsu M, Umemura T, Ichijo T, Matsumoto A, Tanaka E, (2010) A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med 49: 991–994 [CrossRef] [PubMed] [Google Scholar]
  • Krishnan G, D’Silva K, Al-Janadi A, (2008) Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol 26: 2406–2408 [CrossRef] [PubMed] [Google Scholar]
  • Montesinos P, Lorenzo I, Martín G, Sanz J, Pérez-Sirvent ML, Martínez D, Ortí G, Algarra L, Martínez J, Moscardó F, de la Rubia J, Jarque I, Sanz G, Sanz MA, (2008) Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 93: 67–74 [CrossRef] [PubMed] [Google Scholar]
  • Mato AR, Riccio BE, Qin L, Heitjan DF, Carroll M, Loren A, Porter DL, Perl A, Stadtmauer E, Tsai D, Gewirtz A, Luger SM, (2006) A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma 47: 877–883 [CrossRef] [PubMed] [Google Scholar]
  • Tsokos GC, Balow JE, Spiegel RJ, Magrath IT, (1981) Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 60: 218–229 [CrossRef] [PubMed] [Google Scholar]
  • Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, Pieters R, Uyttebroeck A, (2003) Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk Lymphoma 44: 77–83 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E, (2010) Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 51: 221–227 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Vincent F, Canet E, Mokart D, Pène F, Kouatchet A, Mayaux J, Nyunga M, Bruneel F, Rabbat A, Lebert C, Perez P, Renault A, Meert AP, Benoit D, Hamidfar R, Jourdain M, Schlemmer B, Chevret S, Lemiale V, Azoulay E, (2015) Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de recherche en réanimation respiratoire en oncohématologie. Nephrol Dial Transplant 30: 2006–2013 [CrossRef] [PubMed] [Google Scholar]
  • Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel, (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149: 578–586 [CrossRef] [PubMed] [Google Scholar]
  • Gbaguidi X, Goodrich L, Roca F, Suel P, Chassagne P, (2016) Bulky solid tumors in elderly adults: beware of spontaneous tumor lysis syndrome. J Am Geriatr Soc 64: 235–237 [CrossRef] [PubMed] [Google Scholar]
  • Wilson FP, Berns JS, (2014) Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis 21: 18–26 [CrossRef] [PubMed] [Google Scholar]
  • Coiffier B, Altman A, Pui CH, Younes A, Cairo MS, (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26: 2767–2778 [CrossRef] [PubMed] [Google Scholar]
  • Mughal TI, Ejaz AA, Foringer JR, Coiffier B, (2010) An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 36: 164–176 [CrossRef] [PubMed] [Google Scholar]
  • Moreau D, (2005) Prise en charge des syndromes de lyse tumorale en réanimation. Réanimation 14: S224–S228 [CrossRef] [Google Scholar]
  • Conger JD, Falk SA, (1977) Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59: 786 [CrossRef] [PubMed] [Google Scholar]
  • Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, Pession A, Rosti G, Santoro A, Zinzani PL, Tura S, (2008) Consensus conference on the management of tumor lysis syndrome. Haematologica 93: 1877–1885 [CrossRef] [PubMed] [Google Scholar]
  • Mehta RL, Pascual MT, Soroko S, Chertow GM; PICARD Study Group, (2002) Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 288: 2547–2553 [CrossRef] [PubMed] [Google Scholar]
  • LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, Moritz ML, (2007) Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 22: 132–135 [CrossRef] [PubMed] [Google Scholar]
  • Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group, (2015) FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 26: 2155–2161 [CrossRef] [PubMed] [Google Scholar]
  • Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, Gemba K, Fujimaki K, Kirito K, Goto T, Fujisaki T, Takeda K, Nakajima A, Ueda T, (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21: 996–1003 [CrossRef] [PubMed] [Google Scholar]
  • Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A, (2013) Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis 62: 481–492 [CrossRef] [PubMed] [Google Scholar]
  • Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown AJr, Laadem A, Seiter K, (2010) Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone: results of a multicenter phase III study. J Clin Oncol 28: 4207–4213 [CrossRef] [PubMed] [Google Scholar]
  • Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H, (2003) Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an International Compassionate Use Study. Cancer 98: 1048–1054 [CrossRef] [PubMed] [Google Scholar]
  • Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, Fishman M, Masino K, Pi J, Mehta J, (2006) Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 37: 997–1001 [CrossRef] [PubMed] [Google Scholar]
  • Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D, (2008) Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 80: 331–336 [CrossRef] [PubMed] [Google Scholar]
  • Giraldez M, Puto K, (2010) A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol 85: 177–179 [PubMed] [Google Scholar]
  • Trifilio SM, Pi J, Zook J, Golf M, Coyle K, Greenberg D, Newman D, Koslosky M, Mehta J, (2011) Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant 46: 800–805 [CrossRef] [PubMed] [Google Scholar]
  • Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE, (2012) A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23: 1640–1645 [CrossRef] [PubMed] [Google Scholar]
  • Coutsouvelis J, Wiseman M, Hui L, Poole S, Dooley M, Patil S, Avery S, Wei A, Spencer A, (2013) Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br J Clin Pharmacol 75: 565–568 [CrossRef] [Google Scholar]
  • Abdullah S, Diezi M, Sung L, Dupuis LL, Geary D, Abla O, (2008) Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. Pediatr Blood Cancer 51: 59–61 [CrossRef] [PubMed] [Google Scholar]
  • Dimeski G, Bird R, (2009) Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis. Clin Chem Lab Med 47: 880–881 [CrossRef] [PubMed] [Google Scholar]
  • Dastych M, Cermáková Z, (2014) Pseudohyperkalaemia in leukaemic patients: the effect of test tube type and form of transport to the laboratory. Ann Clin Biochem 51: 110–113 [CrossRef] [Google Scholar]
  • Will A, Tholouli E, (2011) The clinical management of tumour lysis syndrome in haematological malignancies: review. Br J Haematol 154: 3–13 [CrossRef] [PubMed] [Google Scholar]
  • Wilson FP, Berns JS, (2012) Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 7: 1730–1739 [CrossRef] [PubMed] [Google Scholar]
  • Choi KA, Lee JE, Kim YG, Kim DJ, Kim K, Ko YH, Oh HY, Kim WS, Huh W, (2009) Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann Hematol 88: 639–645 [CrossRef] [PubMed] [Google Scholar]
  • Canet E, Cheminant M, Zafrani L, Thieblemont C, Galicier L, Lengline E, Schnell D, Reuter D, Darmon M, Schlemmer B, Azoulay E, (2014) Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome? Leuk Lymphoma 55: 2362–2367 [CrossRef] [PubMed] [Google Scholar]
  • Meeks MW, Hammami MB, Robbins KJ, Cheng KL, Lionberger JM, (2016) Tumor lysis syndrome and metastatic melanoma. Med Oncol Northwood Lond Engl 33: 134 [CrossRef] [Google Scholar]
  • Soares M, Feres GA, Salluh JIF, (2009) Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics 64: 479–481 [CrossRef] [PubMed] [Google Scholar]
  • Sanford E, Wolbrink T, Mack J, Rowe RG, (2016) Severe tumor lysis syndrome and acute pulmonary edema requiring extracorporeal membrane oxygenation following initiation of chemotherapy for metastatic alveolar rhabdomyosarcoma. Pediatr Blood Cancer 63: 928–930 [CrossRef] [PubMed] [Google Scholar]
  • Sánchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, Johnson RJ, Herrera-Acosta J, (2006) Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 15: 30–33 [CrossRef] [PubMed] [Google Scholar]
  • Shimada M, Johnson RJ, May WS, Lingegowda V, Sood P, Nakagawa T, Van QC, Dass B, Ejaz AA, (2009) A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant 24: 2960–2964 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.